Sign inCreate account

Report workspace

Add to folder
NCT02084381COMPLETEDanonymous

Permeability Enhancement to Reduce Chronic Inflammation _ Medium Cut Off (MCO) (Study no 1502)

Sponsor

Source record

Vantive Health LLC

Phase

Source record

Completed

Modality

AI-normalized

medical device

Target

AI-normalized

Medium cut-off dialysis membrane (MCO-Ci 400) designed to enhance permeability for molecules up to 45 kDa while limiting albumin permeability (68 kDa), aimed at reducing chronic inflammation in end-stage renal disease patients.

Indication / condition

AI-normalized

Chronic Kidney Failure

Intervention

Source record

MCO-Ci 400, Revaclear 400

Source & freshness

Source record

NCT ID

NCT02084381

Original source

ClinicalTrials.gov

Source last updated

Mar 13, 2025

Ingested at

Jun 16, 2026

Internal sync

Jun 16, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02084381

Title

Permeability Enhancement to Reduce Chronic Inflammation _ Medium Cut Off (MCO) (Study no 1502)

Sponsor

Vantive Health LLC

Status

COMPLETED

Phase

Completed

Condition raw

Chronic Kidney Failure, Chronic Inflammation

Condition normalized

Chronic Kidney Failure, Chronic Inflammation

Modality raw

medical device

Modality normalized

medical device

Target raw

Medium cut-off dialysis membrane (MCO-Ci 400) designed to enhance permeability for molecules up to 45 kDa while limiting albumin permeability (68 kDa), aimed at reducing chronic inflammation in end-stage renal disease patients.

Target normalized

Medium cut-off dialysis membrane (MCO-Ci 400) designed to enhance permeability for molecules up to 45 kDa while limiting albumin permeability (68 kDa), aimed at reducing chronic inflammation in end-stage renal disease patients.

Interventions

MCO-Ci 400, Revaclear 400

Public preview

Source record

The MCO-Ci 400 represents a novel approach in hemodialysis treatment, potentially addressing chronic inflammation in patients with end-stage renal disease (ESRD). Given the increasing prevalence of chronic kidney disease (CKD) and the limitations of current dialysis technologies, this innovation could capture significant market share. The collaboration with established entities such as Baxter Healthcare and Gambro Dialysatoren enhances credibility and market access. The completion of this trial positions Vantive Health LLC favorably for potential partnerships or acquisitions, especially if the results demonstrate significant clinical benefits over existing high-flux dialysis membranes.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Permeability Enhancement to Reduce Chronic Inflammation _ Medium Cut Off (MCO) (Study no 1502)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT02084381

Status

COMPLETED

Phase

Completed

Sponsor

Vantive Health LLC

Executive brief

Investment-Ready Snapshot

The MCO-Ci 400 represents a novel approach in hemodialysis treatment, potentially addressing chronic inflammation in patients with end-stage renal disease (ESRD). Given the increasing prevalence of chronic kidney disease (CKD) and the limitations of current dialysis technologies, this innovation could capture significant market share. The collaboration with established entities such as Baxter Healthcare and Gambro Dialysatoren enhances credibility and market access. The completion of this trial positions Vantive Health LLC favorably for potential partnerships or acquisitions, especially if the results demonstrate significant clinical benefits over existing high-flux dialysis membranes.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 13, 2025
Internal syncJun 16, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02084381

Indication

Chronic Kidney Failure

Modality

medical device

Target

Medium cut-off dialysis membrane (MCO-Ci 400) designed to enhance permeability for molecules up to 45 kDa while limiting albumin permeability (68 kDa), aimed at reducing chronic inflammation in end-stage renal disease patients.

Intervention

MCO-Ci 400, Revaclear 400

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.